An analysis of whether Bestifan (Viliru) can be used in combination with other anti-tumor drugs

Belzutifan (Belzutifan) is a new type of HIF-2α inhibitor, which was first approved for the treatment of VHL disease-related renal cell carcinoma, hemangioblastoma and pancreatic neuroendocrine tumors. Single-agent therapy has shown good safety and efficacy, but for more complex advanced solid tumors, single-agent regimens are often difficult to completely control the disease. Therefore, researchers have begun to explore the combination of bezotivan and other anti-tumor drugs in order to further improve the efficacy and delay the occurrence of drug resistance.

In indications such as renal cancer, bezutivan has been tried in combination with tyrosine kinase inhibitors (TKI) such as cabozantinib and axitinib. The theoretical basis is that HIF-2α is highly related to the VEGF pathway. Bezotifan can reduce angiogenesis signals after inhibiting HIF-2α, while VEGF inhibitors directly block angiogenesis, and the two may have a synergistic effect. Early clinical studies suggest that this type of combination regimen is superior to single drugs in terms of response rate and disease control rate, but it is also accompanied by higher toxic and side effects, and it is necessary to balance efficacy and tolerability in clinical application.

Immune checkpoint inhibitors (ICI) such as PD-1/PD-L1 antibodies are currently an important means of treating advanced tumors. HIF-2α pathway is closely related to the immune microenvironment, and its inhibition may improve the immunosuppressive state of tumors, thereby enhancing the efficacy of ICI. Existing early trials show that the combination of bezotifan and PD-1/PD-L1 inhibitors may play an additional role in some drug-resistant patients, but more randomized controlled studies are still needed to verify its long-term safety and effectiveness.

In general, bezotivan has the potential to be combined with a variety of anti-tumor drugs, but it is still in the clinical exploration stage and has not yet formed a standardized protocol. If clinical patients consider combination therapy, they should choose whether to participate in relevant clinical trials under the guidance of a professional doctor and based on their individual condition and tolerance. In the future, as more phase III clinical trial results are announced, the combination of bezotifan may become a new standard for the treatment of some tumors, bringing better treatment effects and more choices to patients.

Reference materials:https://www.drugs.com/